DaVita Inc. (NYSE:DVA) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 19.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,940 shares of the company's stock after selling 9,498 shares during the period. New York State Teachers Retirement System's holdings in DaVita were worth $6,110,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of DaVita by 16.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 712 shares of the company's stock worth $107,000 after buying an additional 101 shares during the period. Jones Financial Companies Lllp raised its stake in shares of DaVita by 28.6% during the 4th quarter. Jones Financial Companies Lllp now owns 517 shares of the company's stock valued at $77,000 after purchasing an additional 115 shares during the period. SBI Securities Co. Ltd. purchased a new stake in DaVita in the fourth quarter valued at approximately $41,000. Keybank National Association OH lifted its holdings in shares of DaVita by 4.7% in the 4th quarter. Keybank National Association OH now owns 2,721 shares of the company's stock worth $407,000 after acquiring an additional 121 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in DaVita by 10.2% during the 4th quarter. Victory Capital Management Inc. now owns 43,272 shares of the company's stock valued at $6,471,000 after purchasing an additional 4,009 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of DVA stock traded up $1.68 during mid-day trading on Tuesday, hitting $144.49. 316,433 shares of the stock were exchanged, compared to its average volume of 806,884. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18. The company has a market cap of $10.91 billion, a PE ratio of 14.32, a price-to-earnings-growth ratio of 0.98 and a beta of 1.11. The firm has a fifty day moving average of $140.10 and a 200 day moving average of $149.20.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter last year, the firm earned $2.26 earnings per share. The business's revenue for the quarter was up 5.0% on a year-over-year basis. Research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial reduced their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.